DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bpxvnh/biologicals_in) has announced the addition of the "Biologicals in Oncology Drug Pipeline Update 2014" report to their offering.
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 908 companies plus partners developing 1620 biological drugs in 3685 developmental projects in cancer.
In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 920 drugs.
Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 631 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 578 out of the 583 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 84 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed # 148
- Registered # 2
- Pre-registration # 10
- Phase III # 127
- Phase II # 394
- Phase I # 436
- Preclinical # 944
- No Data # 18
- Suspended # 28
- Ceased # 920
For more information visit http://www.researchandmarkets.com/research/bpxvnh/biologicals_in